WithdrawnNCT01448499
Clozapine Versus Amisulpride in Treatment-resistant Schizophrenia Patients
Medication studyAges 18–65Israel
Understand this study
Who could participate?
Listed age limits: 18 years to 65 years.
- Listed locations
- Petah TikvaSee all locations and recruitment
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateOctober 2011
- Recruitment status
- Withdrawn
- Enrollment listed in the registry
- 0
- Sponsor
- Geha Mental Health Center
- Sponsor type
- Hospital / academic medical center
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Not clearly listed
- Locations
- Israel
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT01448499
- Official title
Show the full official title
Clozapine Versus Amisulpride Versus Their Combination in the Treatment of Drug-resistant Schizophrenia Patients
Recruitment & locations
WithdrawnThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Petah Tikva
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Geha Mental Health Center, a hospital or academic medical center.
Does this study involve medication?
Yes. The study involves medication, including Clozapine, Amisulpride and Clozapine+Amisulpride.
Who can participate?
Listed age limits: 18 years to 65 years.
Is this study still recruiting?
The registry lists this study as withdrawn.
Want to explore more studies?
Explore studiesRelated studies
A Study Evaluating the Efficacy of Xanomeline/Trospium (XT) on Cognitive Impairment After 24 and 52 Weeks of Treatment in Adult Participants With Schizophrenia
Bexarotene and Fenretinide as Addition to Antipsychotic Treatment in Schizophrenia Patients